Phase 3 N=65 Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty
Osteoarthritis · Intraoperative Bleeding
Primary: Primary Intra-operative Blood Loss — 100.00; 65.00; 142.80; 100.00 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=129 Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Freedom From Any Atrial Arrhythmias — 24; 23 Participants — p=.83
Phase 4 N=60 Improving Sleep and Psychological Functioning in People With Depression and Insomnia
Sleep Initiation and Maintenance Disorders · Depression
Primary: Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings — 0.81; 1.2 units on a scale
Phase 2 N=81 Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
Iron Deficiency · Fibromyalgia
Primary: Proportion of Patients With a ≥13 Point Improvement in FIQR Score — 30; 26 Participants
Phase 4 N=60 Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients
Moderate to Advanced Chronic Periodontitis
Primary: Change in Interproximal Bone Height Loss, Probing Depth and Clinical Attachment Level Over 24 Months — 3.78; 3.87; 3.57; 3.8 mm
N/A N=7 A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU
Critically Ill · Respiratory Failure
Primary: Safety and Feasibility of Inspiratory Muscle Training — 3; 3 Participants
N/A N=163 Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse® Ultra vs Restylane® for Correction of NLF
Nasolabial Fold Correction
Primary: Primary Efficacy Variable is Change From Baseline to Visit 6/Week 24 in Wrinkle Severity Rating Scale (WSRS) Score — 1.02; 0.91 scores on a scale — p=0.0130
N/A N=84 Cognitive ADHD Videogame Exploratory Study
Attention Deficit Hyperactivity Disorder
Primary: Reaction Time in EVO Gameplay — 520; 480 Reaction time (ms) — p=0.008
Phase 2 N=29 The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor
Obstetric Labour, Premature
Primary: Number of Participants With Vital Sign Values of Potential Clinical Concern — 2; 4; 0; 3 Participants
Phase 2 N=342 A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
HIV Infections
Primary: Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I) — 90.0; 93.0; 71.4; 85.4 Percentage of participants
N/A N=50 Oral Nifedipine Versus Oral Labetalol
Severe Postpartum Hypertension
Primary: Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication — 37.6; 38.2 hours
N/A N=59 Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
Breast Cancer
Primary: Mean Percent Positive Proximity Ligation Assays of All Tumor Protein p53-wild Type Breast Tumors in Participants by Treatment Arm — 27.0; 4.4 percentage of positive PLA
N/A N=662 Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents
HIV Infections · Sexually Transmitted Diseases
Primary: Self-report of Ever Having Sexual Intercourse — 39; 40; 44; 31 Participants — p=.03
Phase 2 N=204 Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants
Evaluation of a Rotavirus Vaccine
Primary: Number of Participants With Vaccine Induced Reactions — 3; 8; 4; 6 Participants
Phase 2 N=28 Subacromial Corticosteroid Injection for Hemiplegic Shoulder Pain
Shoulder Pain
Primary: BPI 12 (Brief Pain Inventory, Question 12) Pain Questionnaire — -1.7; -2.2; -4.7 units on a scale — p=0.16